Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease

Cited by (1,004)

Items 101–200 of 1,004

1. Retromer in Alzheimer disease, Parkinson disease and other neurological disorders
   Scott A. Small, Gregory A. Petsko · 2015 · Nature reviews. Neuroscience
2. Case–control association mapping by proxy using family history of disease
   Liu, Jimmy Z, Erlich, Yaniv, Pickrell, Joseph K · 2017 · Nature Genetics
3. Animal models of α-synucleinopathy for Parkinson disease drug development
   James B. Koprich, Lorraine V. Kalia, Jonathan M. Brotchie · 2017 · Nature reviews. Neuroscience
4. Parkinson’s disease: proteinopathy or lipidopathy?
   Saranna Fanning, Dennis J. Selkoe, Ulf Dettmer · 2020 · npj Parkinson s Disease
5. The Genetics of Parkinson’s Disease and Implications for Clinical Practice
   Jacob Oliver Day, Stephen Mullin · 2021 · Genes
6. Novel genetic loci underlying human intracranial volume identified through genome-wide association
   H. Adams, D. Hibar, V. Chouraki, J. Stein, P. Nyquist, Miguel E. Rentería, S. Trompet, A. Arias-Vásquez, S. Seshadri, S. Desriviéres et al. · 2016 · Nature Neuroscience
7. Genetic variants associated with longitudinal changes in brain structure across the lifespan
   Rachel M. Brouwer, Marieke Klein, Katrina L. Grasby, Hugo Gerard Schnack, Neda Jahanshad, Jalmar Teeuw, Sophia I. Thomopoulos, Emma Sprooten, Carol E. Franz, Nitin Gogtay et al. · 2022 · Nature Neuroscience
8. Evaluation of Models of Parkinson's Disease
   Shail Adrian Jagmag, Naveen Tripathi, Sunil Dutt Shukla, Sankar Maiti, Sukant Khurana · 2016 · Frontiers in Neuroscience
9. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era
   Verstraeten, Aline, Theuns, Jessie, Van Broeckhoven, Christine · 2015 · Trends in Genetics
10. Structure, function and toxicity of alpha‐synuclein: the Bermuda triangle in synucleinopathies
    Anna Villar‐Piqué, Tomás Lopes da Fonseca, Tiago F. Outeiro · 2015 · Journal of Neurochemistry
11. CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study
    The Parkinson’s Progression Marker Initiative, Ju‐Hee Kang, Brit Mollenhauer, Christopher S. Coffey, Jon B. Toledo, Daniel A. Weintraub, Douglas R Galasko, David John Irwin, Vivianna M. Van Deerlin, Alice S. Chen‐Plotkin et al. · 2016 · Acta Neuropathologica
12. Inflammation is genetically implicated in Parkinson’s disease
    Dzamko, N., Geczy, C.L, Halliday, G.M · 2015 · Neuroscience
13. Glucocerebrosidase and Parkinson disease: Recent advances
    Anthony H.V. Schapira · 2015 · Molecular and Cellular Neuroscience
14. Large-scale GWAS identifies multiple loci for hand grip strength providing biological insights into muscular fitness
    Sara M. Willems, Daniel J. Wright, Felix R. Day, Katerina Trajanoska, Peter K. Joshi, John A. Morris, Amy M. Matteini, Fleur C. Garton, Niels Grarup, Nikolay Oskolkov et al. · 2017 · Nature Communications
15. The genetic landscape of Parkinson's disease
    Ariane Lunati, Suzanne Lesage, Alexis Brice · 2018 · Revue Neurologique
16. Microglia Response During Parkinson’s Disease: Alpha-Synuclein Intervention
    Sara Almeida Ferreira, Marina Romero‐Ramos · 2018 · Frontiers in Cellular Neuroscience
17. Recent progress of drug nanoformulations targeting to brain
    Abdur Rauf Khan, Xiaoye Yang, Manfei Fu, Guangxi Zhai · 2018 · Journal of Controlled Release
18. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration
    João Paulo Lima Daher, Hisham Abdelmotilib, Xianzhen Hu, Laura A. Volpicelli‐Daley, Mark S. Moehle, Kyle B. Fraser, Elie Needle, Yi Chen, Stefanus J. Steyn, Paul Galatsis et al. · 2015 · Journal of Biological Chemistry
19. LRRK2 links genetic and sporadic Parkinson's disease
    Jillian H. Kluss, Adamantios Mamais, Mark Cookson · 2019 · Biochemical Society Transactions
20. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome
    Catherine S. Storm, Demis A. Kia, Mona Mohammad Almramhi, Sara Bandrés‐Ciga, Chris Finan, Alastair John Noyce, Rauan B. Kaiyrzhanov, Ben Middlehurst, Manuela M. X. Tan, Henry Houlden et al. · 2021 · Nature Communications
21. Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD
    Boris Kantor, Lidia Tagliafierro, Jeffrey T. Gu, Madison E. Zamora, Ekaterina Ilich, Carole Grenier, Zhiqing Y. Huang, Susan K. Murphy, Ornit Chiba‐Falek · 2018 · Molecular Therapy
22. Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?
    Xin Du, Terence Y. Pang · 2015 · Frontiers in Psychiatry
23. The role of <i>TREM2</i> R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease
    Lill, Christina M., Rengmark, Aina, Pihlstrøm, Lasse, Fogh, Isabella, Shatunov, Aleksey, Sleiman, Patrick M., Wang, Li‐San, Liu, Tian, Lassen, Christina F., Meissner, Esther et al. · 2015 · Alzheimer's &amp; Dementia
24. A Missense LRRK2 Variant Is a Risk Factor for Excessive Inflammatory Responses in Leprosy
    Vinicius M. Fava, Jérémy Manry, Aurélie Cobat, Marianna Orlova, Nguyen Van Thuc, Nguyen Ngoc Ba, Vu Hong Thai, Laurent Abel, Alexandre Alcaïs, Erwin Schurr et al. · 2016 · PLoS neglected tropical diseases
25. Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study
    Nalls, Mike A, McLean, Cory Y, Rick, Jacqueline, Eberly, Shirley, Hutten, Samantha J, Gwinn, Katrina, Sutherland, Margaret, Martinez, Maria, Heutink, Peter, Williams, Nigel M et al. · 2015 · The Lancet Neurology
26. M1 and M2 immune activation in Parkinson’s Disease: Foe and ally?
    Mark S. Moehle, Andrew B. West · 2014 · Neuroscience
27. Insights into Neuroinflammation in Parkinson’s Disease: From Biomarkers to Anti-Inflammatory Based Therapies
    Natália Pessoa Rocha, Aline Silva de Miranda, Antônio Lúcio Teixeira · 2015 · BioMed Research International
28. D NAJC 6 M utations A ssociated W ith E arly‐ O nset P arkinson's D isease
    Simone Olgiati, Marialuisa Quadri, Mingyan Fang, Janneke P.M.A. Rood, Jonas Alex Morales Saute, Hsin Fen Chien, Christian G. Bouwkamp, Josja Graafland, Michelle Minneboo, Guido J. Breedveld et al. · 2015 · Annals of Neurology
29. Ser(P)‐1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease
    Kyle B. Fraser, Ashlee Brooke Rawlins, Rachel G. Clark, Roy N. Alcalay, David G. Standaert, Nianjun Liu, Andrew B. West · 2016 · Movement Disorders
30. Tau Pathology in Parkinson's Disease
    Xue Zhang, Fei Gao, Dongdong Wang, Chao Li, Yi Fu, Wei He, Jianmin Zhang · 2018 · Frontiers in Neurology
31. Neurodegenerative Disease and the NLRP3 Inflammasome
    Jonathan A. Holbrook, Heledd Jarosz-Griffiths, Emily A. Caseley, Samuel J Lara Reyna, James A. Poulter, Caroline H. Williams‐Gray, Daniel Gavin Peckham, Michael McDermott · 2021 · Frontiers in Pharmacology
32. Artificial intelligence in neurodegenerative disease research: use of IBM Watson to identify additional RNA-binding proteins altered in amyotrophic lateral sclerosis
    Nadine Bakkar, Tina Kovalik, Ileana Lorenzini, Scott Spangler, Alix M.B. Lacoste, Kyle Sponaugle, Philip Ferrante, Elenee Argentinis, Rita Sattler, Robert P. Bowser · 2017 · Acta Neuropathologica
33. Ferroptosis in Parkinson's disease: Molecular mechanisms and therapeutic potential
    Xv-shen Ding, Li Gao, Zheng Han, Simona Eleuteri, Wei Shi, Yun Shen, Zi-yao Song, Mingming Su, Qian Yang, Yan Qu et al. · 2023 · Ageing Research Reviews
34. An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation
    Brundin, L, Sellgren, C M, Lim, C K, Grit, J, Pålsson, E, Landén, M, Samuelsson, M, Lundgren, K, Brundin, P, Fuchs, D et al. · 2016 · Translational Psychiatry
35. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models
    Andreas Weihofen, Yuting Liu, Joseph W. Arndt, Christian Huy, Chao Quan, Benjamin A. Smith, Jean‐Luc Baeriswyl, Nicole Cavegn, Luzia Senn, Lihe Su et al. · 2018 · Neurobiology of Disease
36. Haplotype-resolved genome sequencing: experimental methods and applications
    Matthew W. Snyder, Andrew Adey, Jacob Otto Kitzman, Jay Shendure · 2015 · Nature Reviews Genetics
37. The Parkinson’s disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway
    Carla F. Bento, Avraham Ashkenazi, María Jiménez-Sánchez, David Chaim Rubinsztein · 2016 · Nature Communications
38. LRRK2 mutations impair depolarization-induced mitophagy through inhibition of mitochondrial accumulation of RAB10
    Fieke Wauters, Tom Cornelissen, Dorien Imberechts, Shaun Martin, Brianada Koentjoro, Carolyn M. Sue, Peter Vangheluwe, Wim Vandenberghe · 2019 · Autophagy
39. Parkinson Sac Domain Mutation in Synaptojanin 1 Impairs Clathrin Uncoating at Synapses and Triggers Dystrophic Changes in Dopaminergic Axons
    Mian Cao, Yumei Wu, Ghazaleh Ashrafi, Amber J. McCartney, Heather Wheeler, Eric A. Bushong, Daniela Boassa, Mark H. Ellisman, Timothy A. Ryan, Pietro V. De Camilli · 2017 · Neuron
40. The role of Ca2+ signaling in Parkinson's disease
    Sofia Zaichick, Kaitlyn M. McGrath, Gabriela Caraveo · 2017 · Disease Models & Mechanisms
41. Phenome-wide association studies across large population cohorts support drug target validation
    Dorothée Diogo, Chao Tian, Christopher S. Franklin, Mervi Alanne-Kinnunen, Michael March, Chris C. A. Spencer, Ciara Vangjeli, Michael E. Weale, Hannele Mattsson, Elina Kilpeläinen et al. · 2018 · Nature Communications
42. LRRK2 at the interface of autophagosomes, endosomes and lysosomes
    Dorien A. Roosen, Mark Cookson · 2016 · Molecular Neurodegeneration
43. NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson’s disease
    Katharine M. von Herrmann, Lucas A. Salas, Eileen M. Martinez, Alison L. Young, Joseph M. Howard, Mary S. Feldman, Brock C. Christensen, Owen Michael Wilkins, Stephen Lee, William F. Hickey et al. · 2018 · npj Parkinson s Disease
44. Impaired intracellular trafficking defines early Parkinson's disease
    Benjamin H.M. Hunn, Stephanie Jane Cragg, J. Paul Bolam, MariaGrazia Spillantini, Richard Wade‐Martins · 2015 · Trends in Neurosciences
45. Seeded assembly <i>in vitro</i> does not replicate the structures of α‐synuclein filaments from multiple system atrophy
    Lövestam, Sofia, Schweighauser, Manuel, Matsubara, Tomoyasu, Murayama, Shigeo, Tomita, Taisuke, Ando, Takashi, Hasegawa, Kazuko, Yoshida, Mari, Tarutani, Airi, Hasegawa, Masato et al. · 2021 · FEBS Open Bio
46. ENIGMA and the individual: Predicting factors that affect the brain in 35 countries worldwide
    P. Thompson, O. Andreassen, A. Arias-Vásquez, C. Bearden, P. Boedhoe, R. Brouwer, R. Buckner, J. Buitelaar, K. Bulayeva, D. Cannon et al. · 2015 · NeuroImage
47. Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts
    Ganqiang Liu, Joseph J. Locascio, Jean‐Christophe Corvol, Brendon Phillip Boot, Zhixiang Liao, Kara Page, Daly Franco, Kyle Burke, Iris E. Jansen, Ana T. Trisini Lipsanopoulos et al. · 2017 · The Lancet Neurology
48. Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1
    Yu‐Chiang Lai, Chandana Kondapalli, Ronny Lehneck, James B Procter, Brian D. Dill, Helen I. Woodroof, Robert Gourlay, Mark W. Peggie, Thomas Macartney, Olga Corti et al. · 2015 · The EMBO Journal
49. Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease
    Andrew B. West · 2017 · Experimental Neurology
50. The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor
    Matthew P Neal, Alexa M. Boyle, Kevin M. Budge, Fayez F. Safadi, Jason R. Richardson · 2018 · Journal of Neuroinflammation
51. Picomolar concentrations of oligomeric alpha-synuclein sensitizes TLR4 to play an initiating role in Parkinson’s disease pathogenesis
    Hughes, Craig D., Choi, Minee L., Ryten, Mina, Hopkins, Lee, Drews, Anna, Botía, Juan A., Iljina, Maria, Rodrigues, Margarida, Gagliano, Sarah A., Gandhi, Sonia et al. · 2019 · Acta Neuropathologica
52. Parkinson’s Disease Genes VPS35 and EIF4G1 Interact Genetically and Converge on α-Synuclein
    Nripesh Dhungel, Simona Eleuteri, Ling-bo Li, Nicholas J. Kramer, Justin William Chartron, Brian J. Spencer, Kori Ann Kosberg, Jerel Adam Fields, Klodjan Stafa, Anthony Adame et al. · 2014 · Neuron
53. Cellular processes associated with LRRK 2 function and dysfunction
    Rebecca L. Wallings, Claudia Manzoni, Rina Bandopadhyay · 2015 · FEBS Journal
54. Genetic predispositions of Parkinson’s disease revealed in patient-derived brain cells
    Jenne Tran, Helena Targa Dias Anastacio, Cédric Bardy · 2020 · npj Parkinson s Disease
55. Inflammation in Parkinson’s disease: role of glucocorticoids
    Herrero, María-Trinidad, Estrada, Cristina, Maatouk, Layal, Vyas, Sheela · 2015 · Frontiers in Neuroanatomy
56. Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study
    Alastair John Noyce, Demis A. Kia, Gibran Hemani, Aude Nicolas, T. Ryan Price, Eduardo De Pablo‐Fernández, Philip Haycock, Patrick Alfryn Lewis, Thomas Foltynie, George Davey Smith et al. · 2017 · PLoS Medicine
57. The prediagnostic phase of Parkinson's disease
    Alastair John Noyce, Andrew John Lees, Anette E. Schrag · 2016 · Journal of Neurology Neurosurgery & Psychiatry
58. Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
    S. Pablo Sardi, Jesse M. Cedarbaum, Patrik Brundin · 2018 · Movement Disorders
59. VPS35, the Retromer Complex and Parkinson’s Disease
    Erin T. Williams, Xi Chen, Darren J. Moore · 2017 · Journal of Parkinson s Disease
60. The UFMylation System in Proteostasis and Beyond
    Yannis Gerakis, Michaela K. Quintero, Honglin Li, Claudio A. Hetz · 2019 · Trends in Cell Biology
61. The Parkinson’s disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability
    Erinc Hallacli, Can Kayatekin, Sumaiya Nazeen, Xiou H. Wang, Zoe R. Sheinkopf, Shubhangi Sathyakumar, Souvarish Sarkar, Xin Jian Jiang, Xianjun Dong, Roberto Di Maio et al. · 2022 · Cell
62. Genetics of restless legs syndrome
    Juliane Winkelmann, Barbara Schormair, Lan Xiong, Patrick A. Dion, David B. Rye, Guy Armand Rouleau · 2002 · Current Neurology and Neuroscience Reports
63. Exosomes: Origins and Therapeutic Potential for Neurodegenerative Disease
    Diana K. Sarko, Cindy E. McKinney · 2017 · Frontiers in Neuroscience
64. microRNA Profiles in Parkinson's Disease Prefrontal Cortex
    Hoss, Andrew G., Labadorf, Adam, Beach, Thomas G., Latourelle, Jeanne C., Myers, Richard H. · 2016 · Frontiers in Aging Neuroscience
65. An updated review of Parkinson's disease genetics and clinicopathological correlations
    Ferreira, M., Massano, J. · 2017 · Acta Neurologica Scandinavica
66. Tobacco smoking and the risk of Parkinson disease
    Benjamin Mappin‐Kasirer, Hongchao Pan, Sarah Lewington, Jennifer Kizza, Richard G. Gray, Robert Clarke, Richard Peto · 2020 · Neurology
67. Exosomal secretion of α-synuclein as protective mechanism after upstream blockage of macroautophagy
    Fussi, Natascha, Höllerhage, Matthias, Chakroun, Tasnim, Nykänen, Niko-Petteri, Rösler, Thomas W., Koeglsperger, Thomas, Wurst, Wolfgang, Behrends, Christian, Höglinger, Günter U. · 2018 · Cell Death &amp; Disease
68. A genome-wide association study in multiple system atrophy
    Anna Sailer, Sonja W. Scholz, Mike A. Nalls, Claudia Schulte, Monica Federoff, T. Ryan Price, Andrew John Lees, Owen A. Ross, Dennis W. Dickson, Kin Ying Mok et al. · 2016 · Neurology
69. A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants
    Katie J. Ryan, Charles C. White, Kruti Rajan Patel, Jishu Xu, Marta Olah, Joseph M. Replogle, Michael Frangieh, Maria Cimpean, Phoebe A. Winn, Allison McHenry et al. · 2017 · Science Translational Medicine
70. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson’s disease
    Maria Nga Nguyen, Dimitri Krainc · 2018 · Proceedings of the National Academy of Sciences
71. The cell biology of Parkinson’s disease
    Nikhil Panicker, Preston Ge, Valina Lynn Dawson, Ted M. Dawson · 2021 · The Journal of Cell Biology
72. Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease
    Lim, Chai K., Fernández-Gomez, Francisco J., Braidy, Nady, Estrada, Cristina, Costa, Cristina, Costa, Silvia, Bessede, Alban, Fernandez-Villalba, Emiliano, Zinger, Anna, Herrero, Maria Trinidad et al. · 2017 · Progress in Neurobiology
73. Glial phagocytic clearance in Parkinson’s disease
    Marie‐Ève Tremblay, Mark Cookson, Laura Civiero · 2019 · Molecular Neurodegeneration
74. Lipid pathway dysfunction is prevalent in patients with Parkinson’s disease
    Jasmin Galper, Nicholas John Dean, Russell Pickford, Simon J.G. Lewis, Glenda Margaret Halliday, Woojin Scott Kim, Nicolas L. Dzamko · 2022 · Brain
75. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation
    Jeanne C. Latourelle, Michael T. Beste, Tiffany C. Hadzi, Robert E. Miller, Jacob N Oppenheim, Matthew Valko, Diane Wuest, Bruce W Church, Iya G. Khalil, Boris Hayete et al. · 2017 · The Lancet Neurology
76. Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils
    Ying Fan, Andrew J.M. Howden, Adil R. Sarhan, Paweł Lis, Genta Ito, Terina N. Martinez, Kathrin Brockmann, Thomas Gasser, Dario R. Alessi, Esther M. Sammler · 2017 · Biochemical Journal
77. α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
    Tracy A. Cole, Hien Tran Zhao, Timothy J. Collier, Ivette M. Sandoval, Caryl E. Sortwell, Kathy Steece‐Collier, Brian F. Daley, Alix Booms, Jack W. Lipton, Mackenzie Welch et al. · 2021 · JCI Insight
78. Lysosomal LAMP proteins regulate lysosomal pH by direct inhibition of the TMEM175 channel
    Jiyuan Zhang, Weizhong Zeng, Yan Han, Wan-Ru Lee, Jen Liou, Youxing Jiang · 2023 · Molecular Cell
79. Developmental regulation of human cortex transcription and its clinical relevance at single base resolution
    Jaffe, Andrew E, Shin, Jooheon, Collado-Torres, Leonardo, Leek, Jeffrey T, Tao, Ran, Li, Chao, Gao, Yuan, Jia, Yankai, Maher, Brady J, Hyde, Thomas M et al. · 2015 · Nature Neuroscience
80. Environment and Gene Association With Obesity and Their Impact on Neurodegenerative and Neurodevelopmental Diseases
    María Teresa Flores-Dorantes, Yael E. Díaz‐López, Ruth Gutiérrez‐Aguilar · 2020 · Frontiers in Neuroscience
81. Glycosphingolipids and Neuroinflammation in Parkinson’s Disease
    Belarbi, Karim, Cuvelier, Elodie, Bonte, Marie-Amandine, Desplanque, Mazarine, Gressier, Bernard, Devos, David, Chartier-Harlin, Marie-Christine · 2020 · Molecular Neurodegeneration
82. Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci
    Tin Aung, Mineo Ozaki, Mei Lee, Ursula M. Schlötzer-Schrehardt, Guðmar Þorleifsson, Takanori Mizoguchi, Robert P. Igo, Aravind Haripriya, Susan Eileen Isabella Williams, Yury Sergeevich Astakhov et al. · 2017 · Nature Genetics
83. Metformin rescues Parkinson’s disease phenotypes caused by hyperactive mitochondria
    Danielle E. Mor, Salman Sohrabi, Rachel L. Kaletsky, William Keyes, Alp Tartici, Vrinda Kalia, Gary W. Miller, Coleen T. Murphy · 2020 · Proceedings of the National Academy of Sciences
84. Tau accelerates α-synuclein aggregation and spreading in Parkinson’s disease
    Pan, Lina, Li, Chunrui, Meng, Lanxia, Tian, Ye, He, Mingyang, Yuan, Xin, Zhang, Guoxin, Zhang, Zhaohui, Xiong, Jing, Chen, Guiqin et al. · 2022 · Brain
85. Membrane trafficking in health and disease
    Rebecca Yarwood, John Hellicar, Philip G. Woodman, Martin Lowe · 2020 · Disease Models & Mechanisms
86. Of Pesticides and Men: a California Story of Genes and Environment in Parkinson’s Disease
    Beate R. Ritz, Kimberly C. Paul, Jeff M. Bronstein · 2016 · Current Environmental Health Reports
87. Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson’s Disease
    Christin Helmschrodt, Sabrina Höbel, Sandra Schöniger, Anne Bauer, Jana Bonicelli, Marieke Gringmuth, Simone A. Fietz, Achim Michael Aigner, Angelika Richter, Franziska Richter · 2017 · Molecular Therapy — Nucleic Acids
88. Epigenetics of dementia: understanding the disease as a transformation rather than a state
    Bryan Maloney, Debomoy K. Lahiri · 2016 · The Lancet Neurology
89. GBA-Associated Parkinson’s Disease and Other Synucleinopathies
    Ziv Gan‐Or, Christopher Liong, Roy N. Alcalay · 2018 · Current Neurology and Neuroscience Reports
90. Parkinson’s Disease: The Emerging Role of Gut Dysbiosis, Antibiotics, Probiotics, and Fecal Microbiota Transplantation
    Sudhir Dutta, Sandeep Verma, Vardhmaan Jain, Balarama Krishna Surapaneni, Rakesh Vinayek, Laila E. Phillips, Padmanabhan P. Nair · 2019 · Journal of Neurogastroenterology and Motility
91. Mitochondria function associated genes contribute to Parkinson’s Disease risk and later age at onset
    Kimberley J. Billingsley, Inês A. Barbosa, Sara Bandrés‐Ciga, John Peter Quinn, Vivien J. Bubb, Charu Deshpande, Juan Antonio Botía, Regina Hertfelder Reynolds, David Zhang, Michael A. Simpson et al. · 2019 · npj Parkinson s Disease
92. Prioritizing Parkinson’s disease genes using population-scale transcriptomic data
    Li, Yang I., Wong, Garrett, Humphrey, Jack, Raj, Towfique · 2019 · Nature Communications
93. The foundation and architecture of precision medicine in neurology and psychiatry
    Harald Juergen Hampel, Peng Gao, Jeffrey L. Cummings, Nicola Toschi, Paul M. Thompson, Yan Hu, Min Cho, Andrea Vergallo · 2023 · Trends in Neurosciences
94. Predictive Big Data Analytics: A Study of Parkinson’s Disease Using Large, Complex, Heterogeneous, Incongruent, Multi-Source and Incomplete Observations
    Dinov, Ivo D., Heavner, Ben, Tang, Ming, Glusman, Gustavo, Chard, Kyle, Darcy, Mike, Madduri, Ravi, Pa, Judy, Spino, Cathie, Kesselman, Carl et al. · 2016 · PLOS ONE
95. Motor and cognitive deficits in aged tau knockout mice in two background strains
    Lei, Peng, Ayton, Scott, Moon, Steve, Zhang, Qihao, Volitakis, Irene, Finkelstein, David I, Bush, Ashley I · 2014 · Molecular Neurodegeneration
96. Advances in Parkinson’s Disease: 200 Years Later
    Natalia López‐González del Rey, Ana Quiroga‐Varela, Elisa Garbayo, Iria Carballo‐Carbajal, Rubén Fernández‐Santiago, Mariana H.G. Monje, Inés Trigo‐Damas, María J. Blanco‐Prieto, Javier Blesa · 2018 · Frontiers in Neuroanatomy
97. Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease
    Yaping Chu, Warren D. Hirst, Howard J. Federoff, Ashley S. Harms, A. Jon Stoessl, Jeffrey H. Kordower · 2023 · Brain
98. Endo-lysosomal dysfunction: a converging mechanism in neurodegenerative diseases
    Chao Wang, Maria A. Telpoukhovskaia, Ben A. Bahr, Xu Chen, Li Gan · 2017 · Current Opinion in Neurobiology
99. Lessons Learned from Whole Exome Sequencing in Multiplex Families Affected by a Complex Genetic Disorder, Intracranial Aneurysm
    Janice L. Farlow, Hai Lin, Laura R. Sauerbeck, Dongbing Lai, Daniel L. Koller, Elizabeth Pugh, Kurt N. Hetrick, Hua Ling, Rachel Kleinloog, Pieter van der Vlies et al. · 2015 · PLoS ONE
100. Common genetic variant association with altered HLA expression, synergy with pyrethroid exposure, and risk for Parkinson’s disease: an observational and case–control study
     George T. Kannarkat, D A Cook, J-K Lee, Jianjun Chang, J Chung, E Sandy, Kimberly C. Paul, Beate R. Ritz, Jeff M. Bronstein, Stewart Alan Factor et al. · 2015 · npj Parkinson s Disease